GlassScriptPhysician profile
Melissa S Sealy
NPI 1811391865
$7,317.53
in general payments reported to CMS, 2019-2025
40 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,319 · 2022: $1,112 · 2023: $1,590 · 2024: $1,606 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,886.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,240.56 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,036.80 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $939.49 | 2021-2025 | |
| Lilly USA, LLC | $673.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $354.41 | 2021-2023 | Trintellix |
| Corium, LLC | $278.71 | 2022-2025 | Azstarys |
| Astellas Pharma US INC | $276.87 | 2021-2025 | Veozah |
| Pfizer INC. | $242.88 | 2021-2025 | |
| Exact Sciences Corporation | $201.21 | 2023-2025 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $183.75 | 2024-2025 | Xelstrym |
| Amgen INC. | $183.40 | 2021-2025 | Otezla, Repatha, Otezla |
| Esperion Therapeutics, INC. | $175.91 | 2021-2025 | Nexletol |
| Shield Therapeutics INC | $175.16 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $165.62 | 2021-2025 | Capvaxive, Belsomra, Gardasil |
| Phathom Pharmaceuticals, INC. | $153.28 | 2024-2025 | Voquezna |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $116.27 | 2025 | Auvelity |
| Antares Pharma, INC. | $106.91 | 2024-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $89.56 | 2021-2023 | |
| Eisai INC. | $74.46 | 2021 | |
| Abbott Laboratories | $70.75 | 2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $60.80 | 2021-2025 | Ozempic |
| Sanofi-Aventis U.S. LLC | $57.48 | 2021-2023 | |
| Amarin Pharma, INC. | $51.10 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.98 | 2023 | |
| Janssen Pharmaceuticals, INC | $45.20 | 2021-2022 | |
| Valinor Pharma, LLC | $37.80 | 2024 | Movantik |
| Bayer Healthcare Pharmaceuticals INC. | $31.16 | 2022-2023 | |
| Baxter Healthcare | $28.33 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Clarus Therapeutics INC. | $26.05 | 2021 | |
| Biogen, INC. | $25.05 | 2023 | Skyclarys |
| Viatris Specialty LLC | $23.07 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $22.25 | 2023 | Quviviq |
| Tolmar, INC. | $18.58 | 2025 | Jatenzo |
| Dexcom, INC. | $17.14 | 2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $15.59 | 2022 | |
| Currax Pharmaceuticals LLC | $14.68 | 2021 | |
| Tris Pharma INC | $14.64 | 2023 | Dyanavel Xr |
| Halozyme INC | $13.90 | 2023 | |
| Acerus Pharmaceuticals Corporation | $12.88 | 2022 | |
| Mylan Specialty L.P. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Sealy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.